8-K: Turn Therapeutics to Present at Healthcare Conferences

Turn Therapeutics Inc. announced upcoming presentations at two major healthcare conferences to provide updates on its dermatology pipeline, including the Phase 2 clinical trial for GX-03 in atopic dermatitis.

Summary

• Turn Therapeutics Inc. (Nasdaq: TTRX) is a clinical-stage biotechnology company focused on developing targeted inflammatory and immunology therapies for dermatology.
• The company's lead investigational therapy, GX-03, is a first-in-class, non-systemic topical inhibitor currently in late-stage development for moderate-to-severe atopic dermatitis (eczema).
• An ongoing Phase 2 clinical trial for GX-03 in eczema is underway, with topline results expected mid-2026.
• Management will present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference on February 25, 2026, and the 46th Annual TD Cowen Healthcare Conference on March 2, 2026.
• An updated investor presentation was posted to the company's website on February 9, 2026.
• GX-03 is also in development for Onychomycosis (toenail fungus), with Phase 3 initiation planned for Q1 2027.
• The eczema market is projected to reach $9.9 billion by 2030 with an 8.8% Compound Annual Growth Rate (CAGR).
• The onychomycosis market is projected to reach $2.82 billion by 2030 with a 7.55% CAGR.
• The company holds 15 issued patents covering composition and/or methods around its API, with protection through 2037, and has various additional applications pending.
• Turn Therapeutics has out-licensed medical devices, including an Antimicrobial Surgical Gauze and Sterile Collagen Powder, which could generate over $70 million in milestone payments plus royalties.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive update, highlighting progress in clinical development and upcoming investor engagement, alongside a strong IP portfolio and non-dilutive revenue streams, though significant future capital will be required for late-stage trials.

Positives

• Upcoming presentations at two major healthcare conferences will increase company visibility and investor engagement.
• The lead investigational therapy, GX-03, is a first-in-class, non-systemic topical inhibitor, potentially offering a safer alternative to systemic treatments for inflammatory skin diseases.
• GX-03 is currently in an ongoing Phase 2 clinical trial for moderate-to-severe eczema, targeting a large and growing market.
• Strong intellectual property portfolio includes 15 issued patents with coverage through 2037 and additional pending applications.
• Phase 1 safety data for GX-03 showed no adverse reactions across over 580 applications, indicating a favorable safety profile.
• Preclinical data demonstrated GX-03 significantly reduced disease severity (57% reduction in IGA over 7 days) and inhibited key inflammatory cytokines (IL-36, IL-31, IL-4) in an in-vivo atopic dermatitis model.
• The proprietary PermaFusion delivery platform enables superior penetration of active ingredients and is API-agnostic, supporting future pipeline expansion.
• Out-licensed medical devices provide a source of potential non-dilutive revenue through over $70 million in milestone payments and royalties.
• GX-03 for Onychomycosis demonstrated high efficacy (70-85%) in a Phase 2 equivalent study with no reported adverse events, suggesting a strong competitive profile against current treatments.
• A vaccine candidate utilizing the PermaFusion platform showed excellent thermostability, with 100% recovery of rVSV-MARV at 14 days ambient temperature and 28 days refrigerated.

Negatives

• The company is a clinical-stage biotechnology company with no current commercialized products from its lead pipeline, meaning no product-generated revenue yet.
• Significant future R&D expenditures are anticipated, with an expected $55-60 million for Phase 3 trials across both eczema and onychomycosis indications.
• The company projects an expected General & Administrative (G&A) burn of $250,000 per month as a public company, totaling $10-13 million through 2028.
• Future milestones, including Phase 3 initiations and market launch, are explicitly stated as subject to successful completion of each phase and capital availability, indicating funding dependency.
• The onychomycosis market faces a patent cliff in 2026 for existing branded topical drugs, which could intensify generic competition upon GX-03's potential market entry.

Risks

• Forward-looking statements are subject to inherent uncertainties, risks, and assumptions that are difficult to predict, including those related to the timing and effectiveness of the company's registration statement.
• There is no guarantee of the success of development programs.
• The company's ability to execute its strategic plan is a risk factor.
• Industry competition poses a challenge.
• Economic factors could impact operations and financial performance.
• Regulatory challenges and uncertainties in clinical development and obtaining regulatory approvals exist.
• There are no guarantees that pipeline products will prove commercially successful.
• Reliance on third-party partnerships and manufacturers introduces operational risks.
• Dependence on patent protections for the PermaFusion platform is critical.
• The ability to access adequate capital is essential for continued operations and development.

Future Outlook

Turn Therapeutics anticipates topline data from its Phase 2 eczema trial by mid-2026, with Phase 3 initiations for both eczema and onychomycosis planned for Q1 2027. The company projects market launches for GX-03 in 2029, targeting significant growth in the eczema and onychomycosis markets, which are expected to reach $9.9 billion and $2.82 billion by 2030, respectively. The company also plans to conduct extended stability and in vivo immunogenicity studies for its vaccine candidate in Q1 2026.

Management Comments

• "Turn Therapeutics is a biotechnology company focused on developing innovative, precision therapies that target the underlying causes of inflammatory diseases with high unmet needs."
• "Their lead investigational therapy, GX-03, is a first-in-class, non-systemic topical inhibitor currently in late-stage development for the treatment of moderate-to-severe atopic dermatitis (eczema)."
• "This therapy is designed to modulate key inflammatory pathways involved in eczema and other inflammatory dermatological conditions."
• "GX-03 has the potential to serve as first-line treatment for Eczema."

Industry Context

StockSavvy.ai notes that Turn Therapeutics is positioning GX-03 in highly competitive but lucrative dermatology markets. The focus on non-systemic, precision immunomodulation for atopic dermatitis and onychomycosis addresses significant unmet needs, particularly given the side effects and limited efficacy of some existing treatments. The patent cliff for current onychomycosis topicals in 2026 creates an opportunity for new entrants like GX-03, provided it demonstrates superior efficacy and safety. The company's PermaFusion platform also shows potential for broader applications, including vaccine thermostability, which could be a significant differentiator in the broader pharmaceutical landscape.

Comparison to Industry Standards

• Current topical onychomycosis products like Jublia (Efinaconazole), Kerydin (Tavaborole), and Penlac (Ciclopirox) have reported efficacies ranging from 6.5% to 17.8%. GX-03 demonstrated ~70% efficacy with once-daily application and ~85% with BID application in a Phase 2 equivalent study, suggesting a potentially superior profile.
• Existing eczema treatments include topical steroids (quick relief but necrosis with consistent use), topical JAK/PDE4 inhibitors (moderate efficacy, side effects, black-box warnings), and biologics (systemic burden, immunosuppression, site reactions). GX-03 aims to offer a localized, non-systemic approach with a favorable safety profile, potentially addressing limitations of current standards.
• The PermaFusion platform's ability to maintain live virus thermostability (rVSV-MARV 100% recovery at 14 days ambient, 28 days refrigerated) compares favorably to current live vaccines often limited by cold-chain requirements and short shelf lives (2-6 hours at room temperature, 2-5 days refrigerated).

Stakeholder Impact

• Shareholders: Potential for increased visibility and investor interest due to conference presentations; long-term value creation if clinical trials are successful; potential dilution from future capital raises.
• Patients (Eczema/Onychomycosis): Potential for new, effective, non-systemic treatment options with a favorable safety profile.
• Employees: Continued employment and potential growth opportunities as pipeline advances.
• Partners (Medline, MIMEDX): Continued collaboration and potential for additional milestone payments and royalties from out-licensed products.

Next Steps

• Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference on February 25, 2026.
• Present at the 46th Annual TD Cowen Healthcare Conference on March 2, 2026.
• Conduct Adaptive Interim Assessment for Phase 2 Eczema trial in March/April 2026.
• Announce Topline Data Readout from Phase 2 Eczema trial mid-2026.
• Initiate Phase 3 trial for Onychomycosis in Q1 2027.
• Initiate Phase 3 trial for Eczema in Q1 2027.
• Conduct Extended Stability & In Vivo Immunogenicity Studies for vaccine candidate in Q1 2026.
• Plan to conduct immunogenicity studies in live cell and animal models for rVSV and H1N1 Influenza.
• Planned launch of GX-03 for Eczema and Onychomycosis in 2029.

Key Dates

Recommendation

The company is a clinical-stage biotech with promising preclinical and early-stage clinical data for its lead asset, GX-03, targeting large dermatology markets. Upcoming conference presentations and mid-2026 Phase 2 data readout for eczema are key near-term catalysts. However, the company is still several years from potential commercialization, requires significant future capital for Phase 3 trials, and faces inherent risks associated with drug development and market competition. A 'hold' recommendation is appropriate to await further clinical data and clarity on funding strategies before making a more definitive investment decision.

Keywords

Turn Therapeutics, TTRX, biotechnology, dermatology, atopic dermatitis, eczema, GX-03, inflammatory diseases, immunology, clinical trial, Phase 2, Onychomycosis, toenail fungus, PermaFusion, IL-36 inhibitor, IL-31 inhibitor, IL-4 inhibitor, biotech, pharmaceuticals, investor presentation, healthcare conference